ADAPT Or Die: Argos Therapeutics On Brink After Phase III Failure
The US firm brings in advisors as it considers its options after the Phase III ADAPT study of its cancer immunotherapy fails even after change to protocol.
You may also be interested in...
Argos Therapeutics lands in the hands of Genexine and SCM Lifescience after the US immunotherapy firm was put up for sale by the Delaware bankruptcy court. The Korean biotechs plan to use the company’s cGMP facilities and experience in large US Phase III trials to accelerate their global market entry.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.